Arkolith/Insider Trading/JNJ/Form 4

Reed John C

EVP, Innovative Medicine, R&DJOHNSON & JOHNSON (JNJ) · full profile →Form 4 · filed Feb 18, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$13.1M
Net Open-Market Flow
-$13.1M
Transactions
15
9 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 17, 2026Sell(S)22K$243.00$5.3M13K
Feb 17, 2026Option exercise(M)30K$156.15$4.7M43K
Feb 17, 2026Sell(S)30K$243.00$7.3M13K
Feb 17, 2026Sell(S)2K$243.00$555K11K
Feb 17, 2026Option exercise(M)22K$157.92$3.4M35K
Feb 15, 2026Option exercise(M)1K—$012K
Feb 15, 2026Tax withholding(F)385$243.45$94K12K
Feb 15, 2026Option exercise(M)2K—$013K
Feb 15, 2026Tax withholding(F)528$243.45$129K13K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 17, 2026Option exercise(M)22K—$022K
Feb 17, 2026Option exercise(M)30K—$060K
Feb 15, 2026Option exercise(M)1K—$01K
Feb 15, 2026Option exercise(M)2K—$04K
Feb 15, 2026Grant(A)49K—$049K
Feb 15, 2026Grant(A)4K—$04K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000200406-26-000039) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML